Eric Van Cutsem, MD, PhD - Biology that Transcends Tumour Type: Integrating Tumour-Agnostic With Tumour-Specific Treatments for HER2-Positive Gastrointestinal Cancers

What this episode covers

For the complete activity, including supporting material, please visit https://www.peervoice.com/VPQ860. Presented by Eric Van Cutsem, MD, PhD; Florian Lordick, MD, PhD; and Lorenza Rimassa, MD. Learning Objectives: Critically evaluate evolving clinical data on biomarker-targeted therapies for advanced gastroesophageal adenocarcinoma (GEA), with particular focus on HER2-positive and other actionable disease subtypes; Appreciate the biologic drivers underlying actionable targets (eg, HER2) and; how drug design and structural innovations translate into antitumour activity; Identify opportunities for evaluating timely use of HER2-directed therapy for advanced HER2-positive gastrointestinal (GI) cancers in later lines.

Distinct summary based on available episode metadata or transcript content.